上海毕得医药科技股份有限公司（以下简称"公司"）于2023 年7月10日召开第一届董事会第十八次会议，审议通过了《关于 变更公司注册资本、经营范围及修订<公司章程>并办理工商变更 登记的议案》。为满足经营发展需要，公司拟对经营范围进行变 更，同时因实施2022年度利润分配方案，公司注册资本变更，因 此公司相应修订了公司章程。具体情况详见公司于2023年7月11 日在上海证券交易所网站（www.sse.com.cn）披露的《上海毕得 医药科技股份有限公司关于变更公司注册资本、经营范围及修订 <公司章程>并办理工商变更登记的公告》（公告编号：2023-019）。 2023年7月26日，本事项经公司2023年第一次临时股东大会审议 通过。 由于市场监督管理局对经营范围登记规范化工作的要求，公 司按照规范条目将经营范围进行了调整，经核准登记的经营范围 与2023年第一次临时股东大会审议通过的无实质性变化。 公司已完成工商变更登记和备案手续，并于近期取得了由上 关于完成工商变更并取得营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担 ...

标题：关于上海毕得医药科技股份有限公司有关事项的监管工作函 证券代码：688073 证券简称：毕得医药 监管类型：监管工作函 涉及对象：上市公司,董事,监事,高级管理人员,控股股东及实际控制人,中介机构及其相关 人员 处分日期：2023-08-10 处理事由：关于上海毕得医药科技股份有限公司董事会秘书离职相关事项的监管工作函 ...

上海毕得医药科技股份有限公司 证券代码：688073 证券简称：毕得医药 公告编号：2023-025 票上市规则》《上市公司股东、董监高减持股份的若干规定》《上 海证券交易所上市公司股东及董事、监事、高级管理人员减持股 份实施细则》等相关规定，并继续遵守其作为高级管理人员在公 司首发上市时做出的相关承诺。 李涛先生在担任公司副总经理、董事会秘书期间，恪尽职守、 勤勉尽责，公司及董事会对李涛先生在任职期间为公司发展所作 出的突出贡献表示衷心感谢！ 特此公告。 关于公司副总经理、董事会秘书辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 上海毕得医药科技股份有限公司（以下简称"公司"）董事 会于近日收到公司副总经理、董事会秘书李涛先生的辞职报告， 李涛先生因个人原因申请辞去公司副总经理、董事会秘书职务， 辞任后不再担任公司任何职务。根据《公司法》《上海证券交易 所科创板股票上市规则》等法律法规以及《公司章程》的规定， 李涛先生的辞职申请自送达公司董事会之日起生效。 李涛先生已完成相关工作和档案文件的交接，其辞职不会对 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥252,455,900.29, representing a year-on-year increase of 42.58%[5] - The net profit attributable to shareholders for Q1 2023 was ¥36,928,240.19, reflecting a growth of 45.22% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥38,966,750.90, which is an increase of 54.64% year-on-year[5] - Total revenue for Q1 2023 reached ¥252,455,900.29, a significant increase of 42.5% compared to ¥177,067,881.79 in Q1 2022[19] - Operating profit for Q1 2023 was ¥43,644,938.15, up 44.9% from ¥30,115,844.41 in the same period last year[20] - Net profit for Q1 2023 amounted to ¥36,928,240.19, representing a 45.4% increase from ¥25,428,402.43 in Q1 2022[20] - Basic and diluted earnings per share for Q1 2023 were both ¥0.57, an increase of 9.62% year-on-year[6] - Basic and diluted earnings per share for Q1 2023 were both ¥0.57, compared to ¥0.52 in Q1 2022, marking a 9.6% increase[21] Research and Development - The total R&D investment for Q1 2023 was ¥16,163,087.87, marking a significant increase of 66.05% compared to the previous year[6] - The R&D investment accounted for 6.40% of operating revenue, up by 0.90 percentage points from the previous year[6] - Research and development expenses for Q1 2023 were ¥16,163,087.87, a 66.1% increase from ¥9,733,638.06 in Q1 2022[20] Assets and Liabilities - The total assets at the end of Q1 2023 were ¥2,425,420,936.29, which is a 2.81% increase from the end of the previous year[6] - Total assets increased from CNY 2,359,206,247.92 to CNY 2,425,420,936.29, representing a growth of approximately 2.8%[17] - Total current assets increased from CNY 2,244,601,787.13 to CNY 2,309,998,099.82, reflecting a growth of approximately 2.9%[16] - Current liabilities increased from CNY 249,070,839.56 to CNY 286,230,254.30, showing a rise of about 15%[17] - Non-current liabilities decreased from CNY 31,208,972.64 to CNY 28,539,034.51, reflecting a decline of approximately 8.6%[17] - The company’s total liabilities increased from CNY 280,279,812.20 to CNY 314,769,288.81, indicating a growth of about 12.3%[17] - Total liabilities increased to ¥317,437,607.11 in Q1 2023, compared to ¥283,052,077.86 in Q1 2022, reflecting a growth of 12.1%[18] - The equity attributable to shareholders at the end of Q1 2023 was ¥2,107,983,329.18, reflecting a 1.53% increase compared to the end of the previous year[6] - Total equity rose to ¥2,107,983,329.18 in Q1 2023, up from ¥2,076,154,170.06 in Q1 2022, indicating a growth of 1.5%[18] Cash Flow - The net cash flow from operating activities for Q1 2023 was -¥21,457,616.26, indicating a decrease of 67.02% year-on-year[6] - In Q1 2023, the cash inflow from operating activities totaled $274,832,209.08, compared to $166,550,481.91 in Q1 2022, representing an increase of approximately 64.9%[24] - The cash outflow from operating activities was $296,289,825.34, up from $231,606,316.14 in the previous year, indicating a rise of about 28%[24] - The net cash flow from operating activities was -$21,457,616.26, an improvement from -$65,055,834.23 in Q1 2022[24] - Cash inflow from investment activities was $3,473,049.81, while cash outflow was $10,475,799.19, resulting in a net cash flow of -$7,002,749.38 for investment activities[25] - The cash inflow from financing activities was $194,243.33, compared to $55,099.20 in Q1 2022, showing an increase of approximately 252%[25] - The net cash flow from financing activities was -$3,045,407.93, slightly improved from -$3,633,084.89 in the same quarter last year[25] - The total cash and cash equivalents at the end of Q1 2023 stood at $1,463,790,926.46, down from $1,495,462,681.26 at the beginning of the quarter[25] Market and Future Outlook - The company experienced strong demand in the drug molecular block and scientific reagent segments, contributing to the overall revenue growth[9] - The company plans to focus on expanding its market presence and enhancing product development in the upcoming quarters[15] Other Financial Metrics - The company reported a significant increase in accounts receivable from CNY 177,028,268.89 to CNY 219,428,069.98, which is an increase of about 23.9%[16] - Inventory rose from CNY 521,860,490.24 to CNY 574,843,179.86, indicating an increase of about 10.1%[16] - Cash and cash equivalents rose from CNY 1,470,945,899.08 to CNY 1,505,956,232.01, marking an increase of approximately 2.4%[16] - The company reported a total operating cost of ¥203,401,460.75 in Q1 2023, which is an increase of 43.9% from ¥141,216,584.11 in Q1 2022[19] - Other comprehensive income for Q1 2023 showed a loss of ¥14,098,118.88, compared to a loss of ¥80,104.28 in Q1 2022[21] - Employee compensation payments increased to $35,142,187.82 from $33,097,076.01, reflecting a rise of about 6.2%[24] - The company experienced a negative impact of -$165,981.23 from exchange rate fluctuations on cash and cash equivalents[25]

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 145,970,727.07, with the parent company reporting a net profit of RMB 93,801,072.91[5]. - The proposed cash dividend is RMB 15.40 per 10 shares (including tax), totaling RMB 99,971,243.68, which represents 68.49% of the annual net profit attributable to shareholders[5]. - The company's operating revenue for 2022 was CNY 833.83 million, representing a 37.55% increase compared to CNY 606.22 million in 2021[26]. - The net profit attributable to shareholders for 2022 was CNY 145.97 million, a 49.60% increase from CNY 97.57 million in 2021[26]. - The basic earnings per share for 2022 was CNY 2.77, up 35.78% from CNY 2.04 in 2021[27]. - The total assets at the end of 2022 were CNY 2.36 billion, a 160.36% increase from CNY 906.13 million at the end of 2021[26]. - The company's R&D expenditure as a percentage of operating revenue was 5.53% in 2022, slightly down from 5.75% in 2021[27]. - The cash flow from operating activities for 2022 was CNY 29.87 million, a significant recovery from a negative cash flow of CNY 64.88 million in 2021[26]. - The weighted average return on equity for 2022 was 14.24%, down from 18.15% in 2021, indicating a decrease of 3.91 percentage points[27]. - The net assets attributable to shareholders increased to CNY 2.08 billion at the end of 2022, a 230.15% increase from CNY 628.86 million at the end of 2021[26]. Research and Development - The company provided comprehensive drug research and development services for global pharmaceutical companies and biopharmaceutical research institutions[14]. - The company focuses on the discovery, development, and commercialization of innovative molecular targeted immunotherapy drugs for cancer treatment[14]. - The company emphasizes the importance of drug molecular building blocks in designing and synthesizing candidate active drug molecules[14]. - The company is engaged in the research and development of new drugs, including the discovery of drug targets and the screening of lead compounds[15]. - The company aims to optimize lead compounds to meet safety and efficacy requirements for new drug development[15]. - The company is involved in preclinical research, which includes chemical synthesis and pharmacological studies[15]. - The company highlights the significance of drug targets in modern new drug development[15]. - The company is committed to developing innovative drugs with independent intellectual property rights[15]. - The company has the capability to provide over 400,000 novel and diverse drug molecular blocks, with a stock of over 86,000 types readily available[37]. - The R&D team expanded to 168 members, with R&D expenses amounting to 46.07 million yuan, reflecting a 32.08% increase year-on-year[40]. Market Expansion and Strategy - The company aims to continue expanding its market presence and investing in new product development to drive future growth[19]. - The company aims to become a leading enterprise in the global molecular block field, actively expanding its presence in the U.S., Europe, and India[43]. - The company plans to enhance inventory management efficiency and expand its global business scale to support new drug development[28]. - The company is exploring partnerships with international firms to enhance its global footprint and leverage new technologies[146]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million allocated for potential deals[148]. - The company plans to develop high-quality serum products as a breakthrough in the life sciences and biopharmaceutical fields[122]. - The company is focusing on the independent research and development of boron-containing drug molecular building blocks, aiming to enhance brand awareness and open overseas markets[129]. Corporate Governance - The board of directors and senior management have confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has not disclosed any special arrangements for corporate governance[8]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective operation of the shareholders' meeting, board of directors, and supervisory board[179]. - The company adheres to strict information disclosure obligations, ensuring timely and accurate communication with investors[135]. - The company held two shareholder meetings in 2022, ensuring compliance with legal procedures and allowing all shareholders to exercise their voting rights[134]. - The company has not reported any changes in shareholding for key executives during the reporting period[140]. - The company has maintained a stable leadership team with no new appointments or departures reported during the year[140]. Environmental and Social Responsibility - The company emphasizes the importance of ESG (Environmental, Social, and Governance) management, integrating it into overall strategy and operations[183]. - The company invested ¥2.1525 million in environmental protection during the reporting period[184]. - The company has established an environmental management system compliant with ISO14001:2015 standards[190]. - The company is not classified as a key pollutant discharge unit and operates in the "M73 Research and Experimental Development" industry, which is not heavily polluting[185]. - There were no administrative penalties received due to environmental issues during the reporting period[186]. Risks and Challenges - The company has outlined various risks and countermeasures in its report, emphasizing the importance of investor awareness regarding investment risks[4]. - The company faces risks related to talent retention and product quality control, which could impact future performance[84][86].

证券代码：688073 证券简称：毕得医药 公告编号：2023-006 上海毕得医药科技股份有限公司 关于召开 2022 年度业绩说明会的公告 一、 说明会类型 会议召开时间：2023 年 04 月 25 日(星期二) 下午 13:00-14:00 会议召开地点：上海证券交易所上证路演中心（网址： 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 04 月 18 日(星期二) 至 04 月 24 日(星期 一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 ir@bidepharmatech.com 进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度 的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在 信息披露允许的范围内就投资者普遍关注的问题进行回答。 二、 说明会召开的时间、地点 （一） 会议召开时间：2023 年 04 月 25 日 下午 13:00-14:00 （二） 会议召开地点：上证路演中心 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏， ...

2022 年第三季度报告 证券代码：688073 证券简称：毕得医药 上海毕得医药科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 219,851,811.08 | 38.87 | 588,523,507.84 | 37.95 | | 归属于上市公司股东的 | 38,843,971.06 | 65.44 | 98,019,929.93 | 46.95 | | 净利润 | | | | | | 归属于上市公司股东的 扣除非经常性损益的净 | 37,115,320.10 | 57.28 ...